BATCH-6620 · HPLC 99.24%
Growth Hormone Axis
CJC-1295
10 mg lyophilized · no DAC · single vial
Modified GHRH (1-29) analog (no DAC) investigated for extended half-life secretagogue signaling.
Select size / variant
Dispatch schedule
$80.00Research use only
ISO-17025 Batch VerifiedLyophilized Stability
Dosing timeline — 12-Weeks
Per-compound administration schedule across 12 weeks.
WK 1 · 100 mcg / night (no DAC)
WK 2 · 100 mcg / night (no DAC)
WK 3 · 100 mcg / night · or 1 mg weekly (DAC)
WK 4 · 100 mcg / night · or 1 mg weekly (DAC)
WK 5 · 100 mcg / night · or 1 mg weekly (DAC)
WK 6 · 100 mcg / night · or 1 mg weekly (DAC)
WK 7 · 100 mcg / night · or 1 mg weekly (DAC)
WK 8 · 100 mcg / night · or 1 mg weekly (DAC)
WK 9 · 100 mcg / night · or 1 mg weekly (DAC)
WK 10 · 100 mcg / night · or 1 mg weekly (DAC)
WK 11 · No administration
WK 12 · No administration
123456789101112
Entrainment
WK 1–2
100 mcg / night (no DAC)
Baseline GHRH tone
Study Arc
WK 3–10
100 mcg / night · or 1 mg weekly (DAC)
Sustained receptor occupancy
Washout
WK 11–12
No administration
Pituitary re-baseline
Kit composition
- 10 mg lyophilized
CJC-1295
Growth Hormone Axis
- 1 × 3 mL
Bacteriostatic Water
Reconstitution diluent
- × 30
U-100 Syringes
Precision administration